| Patient | Charles Darwin |
|---|---|
| Date of birth | 1809-02-12 |
| Identifiers | MRN HR-NI003-SYN-TD; SSN (made up) 000-03-2967 |
| Document date | 1849-07-21 |
| Author | Bernard Ashworth, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Preventive health visit; no new complaints. [S]
Mr. Darwin is a 40-year-old man with a provisional diagnosis of cyclic vomiting syndrome who comes for his preventive health visit, six weeks after his three-month review. He has had no vomiting episode since then and no emergency visits this year since starting treatment. He takes amitriptyline 75 mg at bedtime with a dry mouth and mild constipation, and carries his sumatriptan and ondansetron. His cold in May cleared in two weeks without an episode. He walks most days and practices relaxation breathing each evening. He completed the health risk assessment in the waiting room. [S]
| Element | Detail |
|---|---|
| Visit | Periodic preventive visit, age 40 |
| Active conditions | Cyclic vomiting syndrome, provisional, on amitriptyline prophylaxis |
| Medicines | Amitriptyline 75 mg at bedtime; sumatriptan nasal spray and ondansetron dissolving tablets for episodes |
| Safety events | No emergency visits or hospital stays since treatment began |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Better than in the winter, in his words |
| Psychosocial | Lives with his family; works from home; less worried about episodes in company since treatment began |
| Tobacco and nicotine | Does not smoke or vape |
| Alcohol | One or two glasses of wine a week (AUDIT-C 2) |
| Cannabis and other drugs | None |
| Physical activity | Walks 30 to 45 minutes most days |
| Nutrition | Regular small meals, as advised for his trigger plan |
| Sleep | Seven to eight hours; mild morning grogginess on amitriptyline |
| Home and road safety | Wears a seat belt; smoke detectors working; no firearms in the home |
| Sexual health | One long-term partner; no new partners |
| Hearing and vision | No concerns |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight up 1 kg since treatment began; no fever or night sweats |
| Eyes | Negative | No blurred vision |
| Ears, nose, mouth, and throat | Positive | Dry mouth on amitriptyline; cold resolved |
| Cardiovascular | Negative | No chest pain or fainting; palpitations only in past prodromes |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Positive | Mild constipation on amitriptyline; wind between episodes less troublesome; no vomiting since the three-month review |
| Genitourinary | Negative | No hesitancy or urinary symptoms |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | No rash or changing moles |
| Neurological | Negative | No headaches or dizziness |
| Psychiatric | Negative | Mood good; PHQ-2 score 0; no thoughts of self-harm |
| Endocrine | Negative | No heat or cold intolerance |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amitriptyline 25 mg oral tablet, one tablet at bedtime | One tablet by mouth at bedtime | Oral route | 1849-04-14 to 1849-04-28 | completed | S |
| Amitriptyline 50 mg oral tablet, one tablet at bedtime | One tablet by mouth at bedtime | Oral route | 1849-04-28 to 1849-05-12 | completed | S |
| Amitriptyline 75 mg oral tablet, one tablet at bedtime | One tablet by mouth at bedtime | Oral route | 1849-05-12 | active | S |
| Sumatriptan 20 mg nasal spray, one spray at the first sign of an episode | One spray in one nostril at the start of the prodrome; may repeat once after 2 hours; no more than 2 sprays a day or 6 a week | Nasal route | 1849-04-14 | active | S |
| Ondansetron 8 mg orally disintegrating tablet at the first sign of an episode | Dissolve one tablet on the tongue at the start of the prodrome, then every 8 hours as needed during an episode | Oral route | 1849-04-14 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1849-07-21 | Body height | 183 | cm | S |
| 1849-07-21 | Body weight | 72.6 | kg | S |
| 1849-07-21 | Body mass index (BMI) [Ratio] | 21.7 | kg/m2 | S |
| 1849-07-21 | Systolic blood pressure | 116 | mm[Hg] | S |
| 1849-07-21 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1849-07-21 | Heart rate | 70 | /min | S |
| 1849-07-21 | Respiratory rate | 14 | /min | S |
| 1849-07-21 | Body temperature | 36.6 | Cel | S |
| 1849-07-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1849-07-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1849-07-21 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 1849-07-21 | Cholesterol [Mass/volume] in Serum or Plasma | 178 | mg/dL | <=200 mg/dL | Normal | S |
| 1849-07-21 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 | mg/dL | >=40 mg/dL | Normal | S |
| 1849-07-21 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 102 | mg/dL | <=129 mg/dL | Normal | S |
| 1849-07-21 | Triglyceride [Mass/volume] in Serum or Plasma | 90 | mg/dL | <=149 mg/dL | Normal | S |
Vital signs recorded on 1849-07-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well and relaxed; weight 72.6 kg, BMI 21.7 |
| Eyes | Pupils equal and reactive; visual acuity 20/20 both eyes |
| Ears, nose, and throat | Canals and drums normal; oral mucosa slightly dry; dentition good |
| Neck | No thyroid enlargement or nodes |
| Cardiovascular | Regular rhythm at 70 per minute; no murmur; blood pressure 116/72 mmHg |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft and non-tender; no masses or organ enlargement |
| Musculoskeletal | Full range of motion; normal gait |
| Skin | No suspicious lesions |
| Neurological | Alert and oriented; no focal deficit |
| Psychiatric | Calm and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cyclic vomiting syndrome, moderate to severe, meeting Rome IV criteria after a normal work-up; provisional clinical diagnosis | active | provisional | R11.15 | S — Synthetic provisional diagnosis at the gastroenterology consultation, anchored to his documented episodic vomiting. It is clinical, with no confirmatory test, and does not confirm any historical theory. |
| Recurrent episodes of nausea and vomiting over more than a year, with prodromal trembling, palpitations, and dizziness, and flatulence and fatigue between episodes; cause under evaluation | resolved | confirmed | R11.2 | S — Synthetic presenting concern at the index visit, superseded by the provisional diagnosis at the six-week visit; the episodic vomiting is documented (D). |
| Common cold, without a vomiting episode; resolved | resolved | confirmed | J00 | S — Synthetic intercurrent illness at an unscheduled visit; chosen because infection is a common trigger of cyclic vomiting and because cold medicines interact with amitriptyline. It does not echo a documented illness. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Depression screening | Completed today | PHQ-2 score 0; PHQ-9 also followed every three months on amitriptyline |
| Anxiety screening | Up to date | GAD-7 6 six weeks ago, down from 8; repeated every three months |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 2; within low-risk limits |
| Unhealthy drug use screening | Completed today | No cannabis or other drug use |
| Tobacco use | Completed today | Does not smoke or vape |
| Blood pressure screening | Completed today | 116/72 mmHg; recheck yearly from 40 |
| Cholesterol screening and statin decision | Completed today | Total cholesterol 178, HDL 58, LDL 102, triglycerides 90 mg/dL; ten-year risk below 5 percent; no statin indicated |
| Diabetes screening | Not indicated | Recommended for adults 35 to 70 with overweight or obesity; BMI 21.7, and glucose was normal in March |
| HIV screening | Ordered | One-time antigen and antibody test, with his consent; no prior result on record |
| Hepatitis C screening | Ordered | One-time antibody test with reflex RNA, with his consent |
| Hepatitis B screening | Ordered | One-time triple panel (surface antigen, surface antibody, and core antibody), drawn before today's vaccine dose |
| Hepatitis B vaccine | Completed today | No record of a prior series; first dose of the two-dose adjuvanted vaccine given today, second dose in one month |
| Influenza vaccine | Due | This season's vaccine due in the autumn |
| COVID-19 vaccine | Due | Discussed; he plans to have this season's vaccine with the influenza vaccine |
| Tdap | Up to date | Booster about seven years ago; next due in about three years |
| HPV vaccine | Not indicated | Routine catch-up ends at 26; at 40 with no new risk, not recommended after discussion |
| Colorectal cancer screening | Not indicated | Starts at 45 |
| Prostate cancer screening | Not indicated | Shared decision starts at 55 |
| Advance care planning | Completed today | Discussed; he will choose a health care agent and return the form |
Immunizations given today: Hepatitis B vaccine (adjuvanted, two-dose series), dose 1 [S]
Guideline basis: Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Six-month review of the cyclic vomiting plan in about seven weeks. Second hepatitis B dose in one month. HIV, hepatitis C, and hepatitis B results by portal message. Next preventive visit in one year. Next scheduled visit 1849-09-08: six-month review of response to prophylaxis. [S]
Advance care planning was introduced as part of routine preventive care. He has no advance directive. He would like the person he lives with to speak for him if he could not, and took home the health care agent form; the agent is not named in this record. He said that what matters most is being able to keep working and to be told plainly what is known and what is not. No treatment decisions were made. [S]